Navigation Links
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
Date:9/10/2007

NEW YORK, Sept. 11 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated (Nasdaq: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that a Phase III study of ERBITUX(R) (Cetuximab) in combination with platinum-based chemotherapy (vinorelbine plus cisplatin) met its primary endpoint of increasing overall survival compared with chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC). This large, randomized multi-national study, known as FLEX (First-Line Treatment for Patients with Epidermal growth factor inhibitor (EGFR)-EXpressing Advanced NSCLC) was conducted by Merck KGaA, Darmstadt, Germany and enrolled patients with Stage IIIB or Stage IV NSCLC who had not previously received chemotherapy.

"Based on the FLEX results, ERBITUX is the only member of the class of epidermal growth factor inhibitors to demonstrate survival in the first-line treatment of patients with advanced non-small cell lung cancer. Previous pivotal trials involving other agents targeting EGFR have failed to demonstrate a survival advantage for these patients," stated Eric K. Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems. "These are important results for lung cancer patients and health care professionals treating this devastating disease, since there have been very few treatment advances for lung cancer in recent years."

"Studies have shown that ERBITUX improves overall survival for patients with certain head and neck ca
'/>"/>

SOURCE ImClone Systems Incorporated; Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
5. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
7. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3)
10. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
11. Replidyne Phase II Pediatric Trial Meets Primary Objective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... Redwood Pharma AB has entered into a ... both the US and China , ... hydrogel technology in its lead chronic Dry Eye therapeutic ... technology offers many unique competitive benefits. At lower temperatures, ... low concentrations of polymer the system can be transitioned ...
(Date:7/2/2015)... BGI a annoncé aujourd,hui que son ... situé à Hong Kong ... Pathologists  (Collège des pathologistes américains, ou CAP). Les ... constituent le premier laboratoire clinique de ... du CAP en Chine, car il satisfait les ...
(Date:7/2/2015)... and VANCOUVER , July 2, 2015 ... EPI) announced today that its common shares have been approved ... under the symbol "EPIX". ESSA will begin trading ... its listing on the TSX Venture Exchange under the symbol ... the common shares on the NASDAQ, each of the Company,s ...
Breaking Medicine Technology:Redwood Pharma Licenses Novel Hydrogel Drug Delivery Technology From Broda Technologies 2BGI obtient la certification du Collège des pathologistes américains (CAP) 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4
(Date:7/6/2015)... ... July 06, 2015 , ... Olive Fertility Centre is proud to announce that ... Award on behalf of the department of Family Practice. , “This award is a ... practicing in. The technology is changing so rapidly and we are also developing new ...
(Date:7/6/2015)... , ... July 06, 2015 , ... ... in southern California, has partnered with Woodbridge Walk-In Urgent Care to offer on-site ... and other serious medical conditions. Screenings are affordable and accurate and run about ...
(Date:7/6/2015)... ... July 06, 2015 , ... Health care systems and genomics projects have generated ... to access and use this “Big Data” to improve health and cut costs is ... of the Mount Sinai Health System in New York City. Physicians will have these ...
(Date:7/6/2015)... ... July 06, 2015 , ... In a split second, breaking ... reduce their risk of having a fracture through the bone health screenings conducted by ... , “We are participating because our residents need this information to remain independent and ...
(Date:7/6/2015)... ... , ... World renowned Los Angeles facial plastic surgeon , Dr. Paul ... treatment solutions. Individuals that want to make multiple changes to their facial appearance are ... each of their needs. , "Anytime I see an opportunity to change the ...
Breaking Medicine News(10 mins):Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 3Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 4Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 5Health News:National Bone Health Screening and Awareness Day 2Health News:Los Angeles Plastic Surgeon, Dr. Paul Nassif, is Now Offering Comprehensive Facial Plastic Surgery Procedures 2
... following release was issued today by the National Autism ... against three families claiming vaccines caused autism in their ... JR and David Kirby reported Tuesday on the story ... following the MMR vaccine. Last week, Banks, parents were ...
... Objectives, Not Undermine ThemJOPLIN, Mo., Feb. 26 ... U.S. House lawmakers to President Barack Obama urging him ... Senior Care (CPSC) said that while the recently passed ... the nation,s long term care workforce, the White House ...
... to save cancer patients, lives can also destroy their ... oncofertility has advanced the ability of doctors to preserve ... are diagnosed with cancer. Yet, many oncologists aren,t familiar ... A leading oncofertility researcher and a breast surgical oncologist ...
... Calif., Feb. 26 Heart disease, stroke, cancer, ... death in America. These conditions cause extreme ... on patients and their families as well as ... Adverse Childhood Experiences (ACE) Study, an ongoing collaboration ...
... Component to Releasing Addictions Program Now AvailableLOS ANGELES, Feb. ... and optimal performance center, announced today the launch of ... - a customized continuing care program providing sober and ... and a new group component to its Releasing ...
... Feb. 26 On Monday, March 2, the ... to become "The Healthiest Company in Green Bay." The firm ... them at that goal.The 30-person agency is collaborating with Health ... ( www.hatwork.com ). The title of "Healthiest Company in Green ...
Cached Medicine News:Health News:On the Heels of Court Ruling Denying Autism-Vaccine Link, U.S. Federal Court Declares MMR Vaccine Caused Autism in a Young Boy 2Health News:Coalition to Protect Senior Care Praises Bipartisan House Effort to Protect Seniors' Nursing Home Care, LTC Workforce 2Health News:New tool guides doctors to save cancer patients' fertility 2Health News:New tool guides doctors to save cancer patients' fertility 3Health News:The Catalyst Foundation's Groundbreaking ACE Study-Based Services Bring Transformational Change to Healthcare 2Health News:Moonview Sanctuary Announces Two New Offerings for Existing and Potential Clients 2Health News:Arketype to Become Green Bay's Healthiest Company in One Year -- Wanna Bet? 2Health News:Arketype to Become Green Bay's Healthiest Company in One Year -- Wanna Bet? 3
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
Medicine Products: